University of Alabama at Birmingham
University of Alabama at Birmingham
Birmingham, AL, United States
Dr. Anirban Kundu earned his M.Tech in biotechnology and Ph.D. in molecular biology, biochemistry, and virology from the Indian Institute of Technology Kharagpur (IIT-Kgp) India. He also worked for a year in the Division of Bioengineering at the National University of Singapore. Dr. Kundu’s work at NUS focused on the mathematical modeling of the active transport process through kidney epithelial cells. After his Ph.D., Dr. Kundu joined the University of Alabama at Birmingham (UAB) Department of Urology as a postdoctoral trainee in 2016. Currently, he is an instructor (junior faculty) in the department. He has studied kidney cancer (RCC) pathobiology for the last seven years. Dr. Kundu studies epigenetic, epitranscriptomic, and metabolic alterations in RCC. He has used various bioinformatics tools, in vitro and in vivo model systems to identify and intervene in druggable axes in kidney cancer. His research goal is to find metabolic and signaling liabilities in kidney cancer that can be targeted with utmost potency using mono-or-combination therapies. Dr. Kundu will join as a faculty at the University of Arizona (UA) Tucson Department of Urology with affiliation from the Arizona Cancer Center and the Department of Cellular and Molecular Medicine in January 2024. His independent research lab will work at the interphase of basic and translational cancer biology to answer important questions regarding kidney cancer progression and novel therapeutic approaches.
Disclosure(s): No financial relationships to disclose